Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 15/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115722 | 1.00 | TSHR (0.43) | TSHRALOX15CASP1CASP7L3MBTL1 | |
| SCHEMBL2113493 | 0.89 | PIK3CD (0.47) | PIK3CDKDM4EALDH1A1 | |
| SCHEMBL2113490 | 0.89 | PIK3CD (0.47) | PIK3CDKDM4EALDH1A1 | |
| SCHEMBL2115003 | 0.80 | CNR2 (0.43) | PIK3CDKDM4EALDH1A1 | |
| SCHEMBL2115000 | 0.80 | CNR2 (0.43) | PIK3CDKDM4EALDH1A1 | |
| SCHEMBL2113787 | 0.77 | SOS1 (0.34) | PIK3CD | |
| SCHEMBL2113779 | 0.77 | SOS1 (0.34) | PIK3CD | |
| SCHEMBL2117642 | 0.75 | PIK3CD (0.44) | TSHRCASP1CASP7PIK3CDKDM4E | |
| SCHEMBL2117648 | 0.75 | PIK3CD (0.44) | TSHRCASP1CASP7PIK3CDKDM4E | |
| SCHEMBL2114960 | 0.74 | PIK3CD (0.43) | TSHRCASP1CASP7PIK3CDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | claimed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | TSHR 1896/4885ALOX15 1348/4885CASP1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.